What drugs does Catalyst make?
Catalyst Pharmaceuticals focuses on developing and commercializing specialized prescription medications targeted at treating rare neuromuscular and neurological diseases. Its primary commercial product is Firdapse, which is approved for treating symptoms of Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder affecting neuromuscular junctions. Additionally, the company commercializes Agamree, an innovative corticosteroid derivative prescribed for Duchenne muscular dystrophy, providing targeted therapeutic relief designed to preserve muscle function and improve clinical outcomes for vulnerable patient populations.
Related FAQs
PaxMedica, Inc. trades on over-the-counter platforms under the ticker symbol PXMD at a market price of approximately $0.0007 per share.
CBL-514 is not currently available for commercial sale or general prescription use, as it remains an investigational drug undergoing clinical development.
Investing in Contemporary Amperex Technology Co. Limited—a global leader in lithium-ion battery manufacturing—from the United States requires navigating the fact that CATL is primarily listed on the Shenzhen Stock Exchange in China.
Investing in Eisai Co., Ltd.
Mind Medicine (MindMed) experienced substantial stock volatility and heightened investor attention driven by major clinical milestones and clinical trial progress for its lead neuropsychiatric candidate, MM120, targeting generalized anxiety disorder ...
Caliway Biopharmaceuticals and associated specialty clinical-stage biopharmaceutical entities typically operate through private venture backing or regional Asian stock exchanges. They do not maintain a primary standalone ticker symbol on major U.S.
Catalyst Pharmaceuticals, Inc. trades on the NASDAQ stock exchange under the official ticker symbol CPRX.
Yes, the Federal Reserve is subjected to regular, routine independent financial audits every year, with its financial statements examined by prominent external accounting firms, and its operations reviewed by the Government Accountability Office.
Long-term biopharmaceutical forecasts for Mind Medicine (MindMed) Inc.
Equity research analysts tracking Mind Medicine (MindMed) evaluate the clinical-stage biopharmaceutical company as a high-risk, high-reward speculative investment.
Investing in Radico Khaitan Limited—a prominent Indian manufacturer of Indian-made foreign liquor and spirits—involves purchasing shares through domestic stock exchanges such as the National Stock Exchange and BSE Limited.
Caliway Biopharmaceuticals focuses on developing innovative pharmaceutical candidates utilizing specialized drug delivery technologies and proprietary active compounds designed to target lipid metabolism, severe medical conditions, and aesthetic indi...
Yes, Phillips Edison & Company, Inc. (PECO) executed a one-for-three reverse stock split of its common stock on July 2, 2021. This action was approved by the company's board of directors and stockholders in June 2021.
The five-dollar stock rule is an informal trading strategy and risk management approach focusing on low-priced equities trading under $5 per share, often categorized as penny stocks or micro-cap securities.
PexaMedica Holdings, Inc., trading under the ticker symbol PXMD, officially completed its initial public offering and began trading its shares on public stock exchanges to raise vital expansion capital.
Caliway Biopharmaceuticals Co., Ltd. (TPEX: 6919) trades at approximately 109.50 New Taiwan Dollars per share.
Investing in Range Resources Corporation, a major independent natural gas and NGL producer operating within the United States energy sector, is accessible via any standard brokerage platform that supports trading on the New York Stock Exchange where ...